Recipharm Advanced Bio and Infant Bacterial Therapeutics (IBT) initiated a process performance qualification (PPQ) at Recipharm’s Cuxhaven microbial manufacturing site to validate commercial production of IBP-9414, IBT’s lead live biotherapeutic product (LBP). The PPQ marks a move toward regulatory submission readiness for what IBT positions as the first live biotherapeutic product globally. Recipharm will supply integrated bacterial capabilities across development and commercial supply, while IBT aims to move from process validation to commercial batches. Both companies highlighted the importance of specialized microbial facilities and analytics for LBPs. The collaboration underscores accelerating industrialization of microbiome therapeutics and the operational challenges and regulatory scrutiny tied to manufacturing live biological products.